Skip to content

News

Posts by Diagnostic Biochips:

Partnership with Cambridge NeuroTech

Partnership with Cambridge NeuroTech

|
|

We would like to announce that we have officially partnered with Cambridge NeuroTech to expand our reach and enhance our distribution network. This collaboration marks a significant milestone for both companies and promises to bring cutting-edge technologies to even more people around the globe.Cambridge NeuroTech will now handle ALL product sales. Moving forward, our 64-channel, 128-channel, Janus Double-sided probes, and Deep Array will now be distributed through Cambridge NeuroTech. This new partnership allows for us to focus on emerging neurotechology which we feel are our top priority to...

Medical Device Network interviews Brian Jamieson

Medical Device Network interviews Brian Jamieson

|
|

GLEN BURNIE // February 16, 2024 - Founder and CTO, Brian Jamieson, shares his thoughts on the potential of brain-computer interfaces. He sheds light on the history of BCIs, but notes that common use amongst larger populations remains unknown in the coming years.

AZoLifeSciences Interview with Brian Jamieson

AZoLifeSciences Interview with Brian Jamieson

|
|

GLEN BURNIE // February 1, 2024 - Brian Jamieson, the founder and CTO of DBC, discusses the company's approach to neural interfacing technology, its impact on brain research, and what lies ahead in the realm of neuroscience in our latest interview.

Forbes Interview with Greg Alden, CEO and President

Forbes Interview with Greg Alden, CEO and President

|
|

GLEN BURNIE // December 27, 2023 - Forbesrecently sat down with Greg Alden, CEO and President of Diagnostic Biochips, to discuss his career, how he brings his unique perspective as a Parkinson’s patient to DBC’s work, and the latest on the treatment horizon for neurodegenerative diseases.

Interview with BioPharmaTrend

Interview with BioPharmaTrend

|
|

GLEN BURNIE // April 7, 2024 - Diagnostic Biochips' Founder and CTO shares insights into the evolving world of brain-computer interfaces (BCIs) in an interview with BioPharmaTrend.